Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature

authors:

avatar Mehrdad Payandeh 1 , avatar Reza Khodarahmi 2 , avatar Masoud Sadeghi 3 , * , avatar Edris Sadeghi 3

Dept. of Hematology, Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

how to cite: Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature. Int J Cancer Manag. 2015;8(2):e80601. 

Abstract

Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy that cause by abnormal proliferation and accumulation of hematopoietic progenitor cells. A 37-year-old woman referred to oncologic clinic with a self-detected mass and pain in her left breast. The stage of tumor was ΙΙΙA. She was treated with the combination of anthracycline and cyclophosphamide for four courses, followed by four courses of paclitaxel with trastuzumab for one year. After 18 months of the first treatment for breast cancer, her bone marrow biopsy was compatible with AML-M2. Here, we are reporting a young woman case with breast cancer that developed AML malignancy during short interval of therapy.

Fulltext

The Full text is available in PDF.